Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Diffuse panbronchiolitis: DPB].

A Azuma1, S Kudoh

  • 1Fourth Dept. Int. Med., Nippon Medical School.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|September 25, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reconsideration of discrepancies between clinical and histopathological features in acute eosinophilic pneumonia.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2015
Same author

Altered cerebellum development and dopamine distribution in a rat genetic model with congenital hypothyroidism.

Journal of neuroendocrinology·2014
Same author

Familial interstitial pneumonia in an adolescent boy with surfactant protein C gene (Y104H) mutation.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2013
Same author

The connected health of cardiovascular medicine: current status and future directions.

QJM : monthly journal of the Association of Physicians·2013
Same author

Historical changes in epidemiology of diffuse panbronchiolitis.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2013
Same author

Induction of EMT-like phenotypes by an active metabolite of leflunomide and its contribution to pulmonary fibrosis.

Cell death and differentiation·2010
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Diffuse panbronchiolitis (DPB) is a chronic airway disease. Low-dose macrolide antibiotics, like erythromycin, significantly improve survival rates for DPB patients.

Area of Science:

  • Respiratory Medicine
  • Immunology
  • Genetics

Context:

  • Diffuse panbronchiolitis (DPB) is a chronic inflammatory airway disease.
  • Historically, DPB had a poor prognosis despite conventional treatments.
  • DPB is characterized by specific diagnostic criteria and pathological findings.

Purpose:

  • To summarize the understanding of Diffuse Panbronchiolitis (DPB).
  • To highlight diagnostic features and pathological hallmarks of DPB.
  • To discuss recent insights into genetic predisposition and therapeutic advancements.

Summary:

  • DPB diagnosis involves symptoms, parasinusitis, radiographic findings, physical signs, pulmonary function tests, and cold hemagglutinin titers.
  • Pathology reveals thickened respiratory bronchioles with inflammatory cell infiltration.

Related Experiment Videos

  • Genetic predisposition, particularly HLA haplotype in East Asians, is noted.

    • Impact:

    • Low-dose erythromycin (400-600 mg/day) is an established therapy improving DPB patient survival.
    • Other 14-membered ring macrolides also demonstrate efficacy in enhancing survival.
    • Understanding DPB's genetics and treatment efficacy is crucial for patient outcomes.